Literature DB >> 23306368

Local and systemic immune responses in pigs intramuscularly injected with an inactivated Mycoplasma hyopneumoniae vaccine.

Silvana Beutinger Marchioro1, Dominiek Maes, Bram Flahou, Frank Pasmans, Rubén Del Pozo Sacristán, Katleen Vranckx, Vesna Melkebeek, Eric Cox, Niels Wuyts, Freddy Haesebrouck.   

Abstract

The immune response induced by intramuscular administration of a commercial inactivated Mycoplasma hyopneumonie whole-cell vaccine (Suvaxyn(®)MH One) was investigated in conventional M. hyopneumoniae-free pigs. The animals were assigned randomly to two groups: non-vaccinated and vaccinated. Pigs in the vaccinated group were injected intramuscularly with the vaccine at 7 days of age, whereas non-vaccinated pigs received physiological saline solution (PBS). Pigs were euthanized and necropsied at 30, 36 and 58 days of age. Blood, bronchoalveolar lavage (BAL) fluid, spleen, lung and bronchial lymph nodes (BLN) were collected. Serum and BAL fluid were tested for the presence of antibodies by ELISA. Monomorphonuclear cells from the peripheral blood and tissues were isolated to quantify the T cell subsets by flow cytometry, and cytokine production by ELIspot and ELISA. Antibodies against M. hyopneumoniae were detected in serum of most vaccinated pigs at 30 days of age. M. hyopneumoniae specific IgG, IgM and IgA were detected in BAL fluid from vaccinated animals, but not from control animals. Significantly higher numbers of IL-12 secreting cells were observed in the lung at day 58 in the vaccinated than in the non-vaccinated group (p<0.05). The number of IL-10 secreting cells from BLN was also higher in the vaccinated group at day 58 (p<0.05). After restimulation in vitro, lymphocytes from BLN and lungs secreted significantly higher levels of IL-12 in the vaccinated group at day 58. These results show that the vaccine induced both systemic and mucosal cellular and humoral immune responses.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306368     DOI: 10.1016/j.vaccine.2012.12.068

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

Review 2.  Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs.

Authors:  Dominiek Maes; Filip Boyen; Bert Devriendt; Peter Kuhnert; Artur Summerfield; Freddy Haesebrouck
Journal:  Vet Res       Date:  2021-05-08       Impact factor: 3.683

3.  Transfer of Mycoplasma hyopneumoniae-specific cell mediated immunity to neonatal piglets.

Authors:  Bert Devriendt; Dominiek Maes; Evelien Biebaut; Lisa Beuckelaere; Filip Boyen; Freddy Haesebrouck; Charles-Oliver Gomez-Duran
Journal:  Vet Res       Date:  2021-06-30       Impact factor: 3.683

4.  Safety and Immunogenicity of a Mycoplasma ovipneumoniae bacterin for domestic sheep (Ovis aries).

Authors:  Jessie C Ziegler; Kevin K Lahmers; George M Barrington; Steven M Parish; Katherine Kilzer; Katherine Baker; Thomas E Besser
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

5.  Induction of mycoplasmal pneumonia in experimentally infected pigs by means of different inoculation routes.

Authors:  Beatriz Garcia-Morante; Joaquim Segalés; Sergio López-Soria; Ana Pérez de Rozas; Henrike Maiti; Teresa Coll; Marina Sibila
Journal:  Vet Res       Date:  2016-05-09       Impact factor: 3.683

6.  Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins.

Authors:  Anneleen M F Matthijs; Gaël Auray; Virginie Jakob; Obdulio García-Nicolás; Roman O Braun; Irene Keller; Rémy Bruggman; Bert Devriendt; Filip Boyen; Carlos A Guzman; Annelies Michiels; Freddy Haesebrouck; Nicolas Collin; Christophe Barnier-Quer; Dominiek Maes; Artur Summerfield
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

7.  Efficacy of three innovative bacterin vaccines against experimental infection with Mycoplasma hyopneumoniae.

Authors:  Anneleen Marguerite Filip Matthijs; Gaël Auray; Filip Boyen; Alexandra Schoos; Annelies Michiels; Obdulio García-Nicolás; Güliz Tuba Barut; Christophe Barnier-Quer; Virginie Jakob; Nicolas Collin; Bert Devriendt; Artur Summerfield; Freddy Haesebrouck; Dominiek Maes
Journal:  Vet Res       Date:  2019-11-08       Impact factor: 3.683

8.  Efficacy of one dose vaccination against experimental infection with two Mycoplasma hyopneumoniae strains.

Authors:  Annelies Michiels; Ioannis Arsenakis; Filip Boyen; Roman Krejci; Freddy Haesebrouck; Dominiek Maes
Journal:  BMC Vet Res       Date:  2017-08-29       Impact factor: 2.741

9.  A novel inactivated vaccine against Lawsonia intracellularis induces rapid induction of humoral immunity, reduction of bacterial shedding and provides robust gut barrier function.

Authors:  F Roerink; C L Morgan; S M Knetter; M-H Passat; A L Archibald; T Ait-Ali; E L Strait
Journal:  Vaccine       Date:  2018-01-11       Impact factor: 3.641

10.  Mucosal and systemic immune responses induced by intranasal immunization of recombinant Bacillus subtilis expressing the P97R1, P46 antigens of Mycoplasma hyopneumoniae.

Authors:  Yongheng Wang; Jialu Wang; Mengyun Zhou; Peng Liu; En Zhang; Yuchen Li; Jian Lin; Zhixin Feng; Qian Yang
Journal:  Biosci Rep       Date:  2019-10-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.